Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKGet Rating) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of NASDAQ EVOK opened at $2.83 on Wednesday. The firm has a market capitalization of $9.45 million, a P/E ratio of -1.03 and a beta of 0.41. Evoke Pharma has a one year low of $1.37 and a one year high of $16.80. The company’s fifty day moving average is $3.46 and its two-hundred day moving average is $2.51. The company has a debt-to-equity ratio of 0.90, a quick ratio of 6.94 and a current ratio of 7.06.

Evoke Pharma Company Profile

(Get Rating)

Evoke Pharma, Inc is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.

Recommended Stories

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.